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Lack of clinical knowledge and financial 
support for adults with attention deficit 
hyperactive disorder (ADHD) are major 
barriers to treatment and diagnosis of 
a condition affecting an estimated one 
million South Africans aged 20 - 50 years.
This is the finding of a thesis completed 
by Dr Renata Schoeman, a psychiatrist 
and Stellenbosch University Business 
School (SBC) top-of-class MBA student. It 
involved a triangulated study: a retrospective 
database analysis of all claims submitted to 
one of the country’s largest medical scheme 
administrators over a 2-year period, a survey 
of all registered psychiatrists (588, with 455 
in private practice) treating adult ADHD 
patients, and a qualitative analysis of key local 
opinion leaders in the fields of psychiatry and 
neurology. She found that, left untreated or 
misdiagnosed, adult ADHD increased the 
risk of other psychiatric phenomena such 
as anxiety, mood disorder and substance 
abuse. At work, people with ADHD displayed 
poor time management, goal setting, stress 
management and organisational skills – 
which had a major impact on colleagues. 
While medical schemes routinely covered 
childhood ADHD, they seldom provided 
benefits for adults, who struggled to afford 
private treatment over and above their 
monthly medical aid costs. This led to huge 
undertreatment. ‘It’s a costly, chronic disorder, 
with significant impact on the quality of life 
of patients and their families,’ she emphasises. 
She cites the condition’s disability-adjusted 
life-years (DALYs) at 424/100 000.
Primary care clinical 
knowledge poor
GPs routinely misdiagnosed or inappro-
priately diagnosed complex presenting 
symp toms. They and many psychiatrists 
(especially those who qualified before adult 
ADHD was recognised as a disorder) had 
limited knowledge about adult ADHD. ‘Also, 
you cannot assess properly in 15 minutes. 
It often presents with comorbidities. Those 
who primarily complain of ADHD symptoms 
are often students and professionals wanting 
the drugs for study purposes, so vigilance 
is needed.’ She described the longstanding 
student practice of misusing ADHD 
medication to improve concentration 
(without being diagnosed with the condition) 
as ‘irresponsible and potentially risky’.
Schoeman has developed a new funding 
model. She’s confident that it will help 
medical aids come to grips with long-
term patient needs, and improve access to 
diagnosis and treatment. She believes that 
medical aid funding reluctance may be due 
to a lack of knowledge, and the risk of over-
diagnosis – which further strengthens the 
case for raising the diagnostic bar.
Schoeman was judged SBC’s top MBA 
student for 2015.
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